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Abstract
The recent identification of multiple new genetic causes of neurological
disorders highlights the need for model systems that give experimental access
to the underlying biology. In particular, the ability to couple disease-causing
mutations with human neuronal differentiation systems would be beneficial.
Gene targeting is a well-known approach for dissecting gene function, but low
rates of homologous recombination in somatic cells (including neuronal cells)
have traditionally impeded the development of robust cellular models of
neurological disorders. Recently, however, CRISPR/Cas9 gene editing
technologies have expanded the number of systems within which gene
targeting is possible. Here we adopt as a model system LUHMES cells, a
commercially available diploid human female mesencephalic cell line that
differentiates into homogeneous mature neurons in 1-2 weeks. We describe
optimised methods for transfection and selection of neuronal progenitor cells
carrying targeted genomic alterations using CRISPR/Cas9 technology. By
targeting the endogenous X-linked  locus, we introduced fourMECP2
independent missense mutations that cause the autism spectrum disorder Rett
syndrome and observed the desired genetic structure in 3-26% of selected
clones, including gene targeting of the inactive X chromosome. Similar
efficiencies were achieved by introducing neurodevelopmental
disorder-causing mutations at the autosomal  locus on chromosomeEEF1A2
20. Our results indicate that efficiency of genetic “knock-in” is determined by
the location of the mutation within the donor DNA molecule. Furthermore, we
successfully introduced an mCherry tag at the  locus to yield a fusionMECP2
protein, demonstrating that larger insertions are also straightforward in this
system. We suggest that our optimised methods for altering the genome of
LUHMES cells make them an attractive model for the study of neurogenetic
disorders.
1 1 2 1
3 3 2
1
2
3
  Referee Status:
 Invited Referees
 version 1
published
15 Nov 2016
 1 2
report report
 15 Nov 2016, :13 (doi: )First published: 1 10.12688/wellcomeopenres.10011.1
 15 Nov 2016, :13 (doi: )Latest published: 1 10.12688/wellcomeopenres.10011.1
v1
Page 1 of 21
Wellcome Open Research 2016, 1:13 Last updated: 25 DEC 2016
F1000Research
 Adrian P. Bird ( )Corresponding author: A.Bird@ed.ac.uk
 Shah RR, Cholewa-Waclaw J, Davies FCJ  How to cite this article: et al. Efficient and versatile CRISPR engineering of human neurons in
 Wellcome Open Research 2016, :13 (doi: culture to model neurological disorders [version 1; referees: 2 approved] 1
)10.12688/wellcomeopenres.10011.1
 © 2016 Shah RR . This is an open access article distributed under the terms of the , whichCopyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 This work was supported by the Wellcome Trust [099841], [091580], [107930], [92076]; Rett Syndrome Research Trust; andGrant information:
the Medical Research Council.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 Competing interests: No competing interests were disclosed.
 15 Nov 2016, :13 (doi: ) First published: 1 10.12688/wellcomeopenres.10011.1
Page 2 of 21
Wellcome Open Research 2016, 1:13 Last updated: 25 DEC 2016
Introduction
The advent of technologies that introduce targeted mutations into 
the genome has dramatically changed the way in which genetic 
diseases can be modelled and studied. The most recent devel-
opment in the genome editing field, the clustered regularly 
interspaced short palindromic repeats (CRISPR) and CRISPR 
associated 9 (Cas9) system, has proven to be extremely successful, 
due in part to its ease of use and efficient implementation in a 
variety of cell lines (Cong et al., 2013; Jinek et al., 2013; Liang 
et al., 2015) and model organisms (Friedland et al., 2013; Gratz 
et al., 2013; Hai et al., 2014; Hwang et al., 2013; Jiang et al., 
2013; Li et al., 2013; Niu et al., 2014; Wang et al., 2013). The 
coupling of CRISPR gene editing technology with human 
induced pluripotent stem cells (iPSCs) has rapidly expanded the 
number of neurological disorders that can be modelled in a human 
neuronal background and is allowing researchers to probe the 
underlying molecular mechanisms in unprecedented detail 
(Howden et al., 2016; Merkert & Martin, 2016; Mungenast 
et al., 2016). In particular, the ability to genetically modify a hiPSC 
line to create isogenic cell lines, which are genetically identical 
(bar the disease causing mutation), and differentiate these into 
neurons for phenotypic analysis is extremely powerful. However, 
despite advances in hiPSC culture and neuronal differentiation pro-
tocols, there are still some limitations to this strategy. One obstacle 
is the large variability of clonal iPS cell lines when they are derived, 
which can have negative downstream effects on CRISPR targeting 
efficiency, single cell cloning and particularly on phenotypic 
outcomes. Furthermore, there is still debate as to the robustness of 
the epigenome in iPSCs after reprogramming (Kim et al., 2010; 
Ohi et al., 2011).
Alternative human neuronal progenitor cell lines are available 
including the SH-SY5Y line and neural stem cells derived from 
fetal human brain or human embryonic stem cells. Yet each of these 
models has drawbacks. SH-5YSY cells are a neuroblastoma cell 
line with multiple chromosomal duplications and deletions (Krishna 
et al., 2014) and neural stem cells take a long time to mature dur-
ing the differentiation process, expressing markers specific for neu-
ronal progenitors for at least four weeks (Shin & Vemuri, 2010; 
Sun et al., 2008; Tong et al., 2016). The LUHMES neuronal pro-
genitor cell line is a recent alternative that is proving to be highly 
useful in the neuroscience field (Lotharius et al., 2002). These 
female “pre-neuronal” cells are forced to proliferate in an imma-
ture state by expression of the retroviral element v-myc (Hoshimaru 
et al., 1996). V-myc expression is under the control of tetracycline 
so by simple administration of the drug to cell culture medium, 
LUHMES cells undergo a rapid and robust differentiation into a 
homogeneous population of electrically active, post-mitotic, mature 
dopaminergic neurons in just 1 week (Lotharius et al., 2002). The 
resulting neurons have thus far been used to model Parkinson’s 
disease (Lotharius et al., 2005; Xiang et al., 2013), for cytotoxicity 
assays (Tong et al., 2016) and for technology development (Dinh 
et al., 2013; Hughes et al., 2014; Ilieva et al., 2013).
In order to make this cell line more widely applicable for the neuro-
science field, it would be beneficial to routinely genetically modify 
LUHMES cells to create a variety of cell lines for disease modelling 
and drug-screening purposes. Historically genetic manipulation via 
homology-directed repair (HDR) of somatic cells has been difficult, 
with the most successful approaches involving rAAV-delivered 
homology arms to produce targeting efficiencies of ~1% (Porteus 
& Baltimore, 2003; Porteus et al., 2003; Russel & Hirata, 1998). 
With the advent of CRISPR technologies, HDR targeting efficien-
cies in somatic cells has increased somewhat, although to different 
extents in different systems, for example 1.3% in primary neona-
tal fibroblasts (Lin et al., 2014), 1.8% in vivo by AAV delivery to 
mouse lung tissue (Platt et al., 2014) and 17% in T cells using Cas9 
ribonucleoprotein complexes (Schumann et al., 2015).
Here we describe a robust and reproducible method for the effi-
cient transfection of LUHMES cells, and demonstrate various 
ways in which this cell line can be genetically manipulated using 
CRISPR engineering to create human models for the study of 
neurological disorders.
Results
Transfection of proliferating LUHMES cells using 
Nucleofection
In this study we sought to edit the endogenous genome of the 
pre-neuronal somatic LUHMES cell line in three ways: i) by dis-
rupting a target gene; ii) by introducing discrete mutations into the 
protein coding region; iii) by adding a relatively large protein tag 
to generate a fusion protein (Figure 1A). Karyotyping confirmed 
that LUHMES cells have a normal diploid chromosome comple-
ment (Supplementary Figure 1A) and RNA FISH demonstrated X 
inactivation to be established in the pre-neuronal cells prior to dif-
ferentiation (Supplementary Figure 1B). As a first step in editing 
the genome, a reproducible method of plasmid transfection needed 
to be established for these cells. LUHMES cells have proven to 
be difficult to transfect (Schildknecht et al., 2013) and as a result 
previous studies relied on lentiviruses. In our hands transient trans-
fection methods such as electroporation, Lipofectamine-2000, 
Neon transfection and JetPrime Polyplus all resulted in cell death 
or extremely low levels of transfection (Ruth R. Shah, Justine 
Cholewa-Waclaw, and Adrian Bird, unpublished report). Nucleo-
fection has previously proven to be successful, but only after 
differentiating the cells for 2 days prior to trypsinisation and 
Nucleofection (Schildknecht et al., 2013). For the generation 
of genetically modified cell lines, this protocol is undesirable as 
any transfected cells will be immediately differentiated into post-
mitotic neurons, and no stock of proliferating, genetically modi-
fied cells remains. In order to optimise Nucleofection conditions in 
proliferating LUHMES neuronal progenitor cells, the Amaxa Basic 
Nucleofector Kit for primary neurons was used with 20 different 
Nucleofection programs to find the optimal balance between trans-
fection efficiency and cell viability (Supplementary Figure 1C). 
Program D33 reproducibly yielded transfection efficiencies of 
25–30%, as judged by the number of GFP-positive cells in the 
population (Figure 1B). Of note, transfection of plasmids that 
have been prepared in an endotoxin-free environment resulted in 
increased cell viability, but purification of plasmids by ethanol 
precipitation did not improve this (Supplementary Figure 1E+F). 
In this way we achieved efficient and reproducible transfection of 
proliferating LUHMES cells using exogenous plasmids.
Generation of a MeCP2 knock-out cell line
We next tested the ability of CRISPR/Cas9 to generate a knock-
out LUHMES cell line. For this the MECP2 locus was chosen. 
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The MeCP2 protein is highly expressed in neurons (Shahbazian 
et al., 2002; Skene et al., 2010) and mutations within this protein 
lead to the autism-spectrum disorder Rett syndrome (Amir et al., 
1999). Multiple mouse models of Rett syndrome have been devel-
oped, including mice containing Rett syndrome-causing point 
mutations (Brown et al., 2016) as well as knock-out alleles (Chen 
et al., 2001; Guy et al., 2001). The MECP2 gene has four exons, 
with different isoforms being expressed from exons 1 and 2. As 
exon 3 is the first shared exon among all isoforms, this was chosen 
for targeting in order to ablate all MeCP2 protein isoforms. Two 
sgRNAs were designed within exon 3 (Figure 2A) and were indi-
vidually cloned into a plasmid that also encodes Cas9 and a puro-
mycin resistance gene (Figure 2B) (Sanjana et al., 2014). LUHMES 
cells were Nucleofected (Supplementary Figure 2A) and after 
selecting for positively transfected cells using puromycin resistance 
both sgRNAs were confirmed to be functional by the T7E1 assay 
(Figure 2C) and single-cell colonies were established by serial dilu-
tion in 96-well plates. The genomic DNA from single cell colo-
nies was extracted and sequenced in order to identify potential 
positive KO clones. The genomic DNA sequencing from two dif-
ferent cell lines is shown in Figure 2D, KO1 has a homozygous 
deletion of 9bp whereas KO2 has a heterozygous deletion of 14bp, 
with the second allele being unaltered. As MECP2 resides on the 
X chromosome and LUHMES cells are female cells with one 
X chromosome already in the inactive state (Supplementary 
Figure 1B), the homozygous 9bp deletion in KO1 suggests that 
the inactive X chromosome can be edited by the CRISPR/Cas9 
system. Overall, out of 13 colonies that were sequenced, 11 
contained INDELs thus giving a targeting efficiency of 85%.
To determine the genotype of the actively expressed MECP2 mRNA 
in these cell lines, cDNA sequencing was performed (Figure 2E). 
The 14bp deletion allele in KO2 appears to reside on the active 
X chromosome as all cDNA sequence reads from this cell line 
contained this out-of-frame deletion, highly indicative of a pro-
tein KO phenotype. Surprisingly the 9bp in-frame deletion in the 
middle of exon 3 of KO1 resulted in the whole of exon 3 being 
removed from the mature mRNA transcript, causing exons 2 and 
4 to be spliced together in-frame. Western blot analysis confirmed 
the complete absence of any full length MeCP2 protein in both cell 
lines (Figure 2G). In order to identify clones that might contain 
truncated protein, Western blot analysis was performed using two 
different antibodies, one against the N-terminus of MeCP2 and 
another against the C-terminus, and this revealed that KO1 has very 
low levels of a truncated protein (Supplementary Figure 2B). Even 
though this cell line cannot technically be referred to as a protein 
KO cell line, the extremely low MeCP2 protein level that remains 
(and the removal of critical residues via deletion of exon 3) prob-
ably results in a cell line that is phenotypically null, as has been 
observed in mice (Chen et al., 2001). Finally, the top off-target loci 
for each sgRNA were sequenced for off-target INDEL formation 
and as expected based on recent findings in hiPSCs (Paquet et al., 
2016), no off-target cutting was observed (Figure 2H). These exper-
iments confirm Cas9-induced INDEL formation to be successful, 
specific and highly efficient in LUHMES cells.
Insertion of Rett syndrome-causing point mutations into 
MECP2 
We also explored the possibility of introducing specific point muta-
tions into LUHMES cells, historically a more challenging proce-
dure for somatic cells (Hendrie & Russell, 2005). The MECP2 locus 
is an ideal candidate for use in optimising CRISPR knock-in (KI) 
conditions as there are a number of disease-causing point muta-
tions throughout the locus (Lyst & Bird, 2015). Furthermore the 
Figure 1. Nucleofection for efficient transfection of LUHMES cells. (A) The aims of this study are to develop methods for genetic 
manipulation of the LUHMES pre-neuronal cell line, which in itself requires methods of transient transfection to be developed. After successful 
genetic modifications have been confirmed, LUHMES cells can then be differentiated into mature neurons for study. (B) Representative 
images of plasmid transfection of LUHMES cells using program D33 with a Nucleofector device. Pictures were taken 47 hours 
post-Nucleofection. Scale bar is 200 µm.
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Figure 2. Generation of MeCP2 knock-out LUHMES cell lines. (A) Schematic representation of the MECP2 locus with the targeting 
sequence of sgRNA A and sgRNA B labelled. Arrowheads indicate sites of double-strand break. (B) Schematic representation of the plasmid 
used to deliver Cas9 and sgRNA to LUHMES cells. (C) T7E1 assay of sgRNA A and sgRNA B. WT: non-transfected wild-type cells. NDC: 
wild-type cells Nucleofected without any DNA. Asterisks indicate non-specific bands. Arrows indicate bands specific to samples containing 
Cas9 and sgRNA. (D) Sequencing of genomic DNA from two LUHMES single-cell clones. Wild-type genomic DNA is in lower case at the 
top. (E) Sequencing of cDNA from two LUHMES single-cell clones. Wild-type cDNA is in lower case at the top. (F) Sequencing of genomic 
DNA from a single LUHMES unedited clone that was transfected with Cas9 and sgRNA B. Wild-type gDNA is in lower case at the top. 
(G) Western blot of MeCP2 protein and Histone H3 loading control from wild-type cells (WT), wild-type cells that went through the 
Nucleofection and cloning process (WTC), KO1 and KO2 cell lines. (H) Sequencing of sgRNA off-target sites in KO1 and KO2 cell lines. 
Numbers next to each locus name indicate the off-target score as determined by crispr.mit.edu.
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manipulation of this X-linked gene offers the opportunity to explore 
the ability of the CRISPR/Cas9 system to genetically manipulate 
genes on the inactive X chromosome.
In the previous experiment serial dilution was used to gener-
ate single cell colonies but we found that this method led to low 
efficiency of cloning and some colonies were derived from more 
than one genetically modified cell line, as several expressed 
alleles were detected in cDNA sequencing (Supplementary 
Figure 2C). In order to improve clonal selection we used FACS 
sorting to cleanly isolate single cells into a 96-well plate. LUHMES 
cells were amenable to this manipulation, with approximately 
50–60% of wells repopulating to produce single-cell colonies.
First, the ability to knock-in the Rett syndrome-causing missense 
mutation of arginine at position 306 to cysteine (R306C) was 
tested (Figure 3A). The R306C mutation itself (CGC➔TGC) cre-
ates a novel target sequence for the restriction enzyme HpyCH4V 
(Figure 3B). This allowed for easy screening of genomic DNA 
from single-cell clones using a restriction fragment length 
polymorphism assay (RFLP), with the positive clones from this assay 
being confirmed by sequencing. Initially, a plasmid targeting vec-
tor containing 2044bp of homology was used to deliver the R306C 
point mutation and a silent PAM-abolishing mutation to prevent 
re-cutting of a recombined allele. Out of 191 single cell clones that 
were screened using the HpyCH4V RFLP assay, 0 appeared to be 
positive (experiment 1 in Table 1). Next a 110bp single-stranded 
Figure 3. Generation of a human neuronal cell line containing a Rett syndrome-causing missense mutation in MECP2. (A) Schematic 
representation of the MECP2 locus with the sgRNA 1 target sequence labelled and the ssODN 1 donor molecule with point mutation alterations 
indicated in upper case. The site of double strand break is labelled with two arrowheads and the distance between the point mutation of 
interest and the double-strand break site is indicated. (B) Schematic representation of the RFLP screening assay used for identifying positive 
knock-in clones. Mutation of arginine at position 306 to cysteine results in the introduction of a novel target sequence for the restriction enzyme 
HpyCH4V. Primers used for PCR amplification are labelled. (C) HpyCH4V digests of the PCR product (Supplementary Figure 3A) to identify 
clones that have gained a novel HpyCH4V target sequence. A positive clone is identified with an asterisk. (D) Sequencing of genomic DNA 
and cDNA from the RFLP-positive cell line confirms the cell line to be MECP2-R306C. (E) Sequencing of the top two off-target sites for sgRNA 
1 in the R306C cell line. Number next to the locus name is the off-target score as calculated by crispr.mit.edu.
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oligodeoxynucleotide (ssODN) was used in combination with 
a non-complementary sgRNA that cuts 6bp away from R306, 
and in this instance 1 cell line out of 69 was positive, giving a 
KI efficiency of 1.6% (Figure 3A+C+D, experiment 2 in Table 1). 
Again analysis of this cell line demonstrated no off-target cutting 
(Figure 3E). An alternative sgRNA:ssODN pair where sgRNA 
2 cuts 31bp away from R306, but the sgRNA and ssODN were 
complementary to one another was also tested (Figure 4A). This 
combination produced two positive R306C cell lines (KI effi-
ciency of 2.9%, experiment 3 in Table 1), but both cell lines con-
tained downstream deletions at the site of the double-strand break 
(DSB) (Figure 4B). These results suggest that a large distance 
between the point mutation and the DSB could be more suscepti-
ble to error-prone recombination and therefore subsequent INDEL 
formation.
In an attempt to increase the efficiency of KI the CRISPR plasmid 
that encodes puromycin resistance was exchanged for a CRISPR 
plasmid that encodes for green fluorescent protein (Ran et al., 
2013b) (Figure 4C). Thus, instead of subjecting the Nucleofected 
LUHMES cells to puromycin selection and FACS sorting, these two 
steps were combined into one by using the presence of GFP in cells 
two days after Nucleofection to identify positively transfected cells 
and to sort them into a 96-well plate. Using this new strategy three 
new Rett syndrome-causing point mutations, R111G, R133C and 
T158M, were targeted using ssODNs (Supplementary Figure 3). 
Two of these three point mutations do not introduce a novel restric-
tion enzyme target sequence and so one was engineered into the 
ssODN for ease of screening. Each 100bp ssODN contained point 
mutations to introduce the following motifs: the mutation of interest, 
a silent PAM abolishing mutation, and a silent mutation to insert a 
novel restriction enzyme target sequence (Supplementary Figure 3). 
All three targeting experiments generated positive cell lines as 
judged by genomic DNA sequencing (Figure 4D,E,F) and as can 
be seen in Table 1, the efficiency of KI for all three point mutations 
is significantly increased relative to the initial efficiency of 1.6%, 
reaching a maximum of 26% for KI of R111G.
As shown in Table 1, several factors could contribute to the large 
variability in targeting efficiency. Firstly, the distance of the 
sgRNA-induced DSB from the point mutation of interest varies, 
and secondly the number of mismatched residues in the ssODN 
that are upstream of the DSB also varies. This latter variable 
would be in line with evidence that mismatches in the non-sgRNA 
binding DNA strand upstream of the PAM are refractory to 
homology-directed repair (HDR) (Richardson et al., 2016). Despite 
uncertainty regarding the exact constraints on efficient KI of 
point mutations using CRISPR technology, KI efficiencies in 
the somatic LUHMES neuronal progenitor cells are sufficient to 
allow the rapid generation of cell lines containing disease-causing 
point mutations with minimal clonal selection and screening.
Insertion of a neurodevelopmental disorder-causing point 
mutation into EEF1A2 
To demonstrate the utility of LUHMES cells as a model system 
for other neurological disorders, and to confirm efficient KI at an 
autosomal locus, we targeted the D252H missense mutation in the 
EEF1A2 gene that causes severe neurodevelopmental delay and 
intellectual disability (Nakajima et al., 2015). The approach was to 
use two sgRNAs that cut 51bp apart, combined with Cas9 nickase 
protein (Ran et al., 2013a) (Figure 4G) and a 200bp ssODN. Again 
the presence of GFP expression in LUHMES cells was used to 
identify positively transfected cells and to sort single cells into 96-
well plates. In this experiment a KI efficiency of 14% was achieved 
and interestingly the D252H positive cell line has a KI on both alle-
les and is therefore a homozygous, true positive cell line (Figure 
4H). The successful knock-in of a point mutation into an autosomal 
locus and subsequent generation of an EEF1A2-D252H cell line 
demonstrates the ease of genetic manipulation of LUHMES cells 
and highlights its utility for modelling a variety of human neuro-
genetic disorders.
Knock-in of a large tag into the endogenous MECP2 locus
Finally, we assessed the ability of the CRISPR/Cas9 system to 
introduce a large tag into an endogenous locus in LUHMES cells. 
Table 1. Point mutation KI efficiencies in the MECP2 locus. PM = point mutation. DSB = double-strand break.
Point 
mutation
Selection, 
plasmid 
amount
Donor molecule 
(ssODN is 10 µM)
sgRNA: 
ssODN
PM ➔ DSB 
distance
Number of 
upstream 
mutations
Number of 
KI clones KI efficiency
1 R306C Puro, 1.2 µg 1.9 µg 2 kb plasmid - 31 bp 1 0/191 0%
2 R306C Puro, 2 µg 4 µl 110 bp ssODN 1 Not comp 5 bp 1 1/69 1.6%
3 R306C GFP, 2.5 µg 8 µl 110 bp ssODN 2 Comp 31 bp 1 2/69 2.9%
4 R111G GFP, 2 µg 10 µl 100 bp ssODN 3 Comp 3 bp 0 7/27 26%
5 R133C GFP, 2 µg 10 µl 100 bp ssODN 4 Comp 6 bp 2 2/54 3.7%
6 T158M GFP, 2 µg 10 µl 100 bp ssODN 5 Comp 4 bp 1 1/18 5.5%
7 T158M GFP, 2 µg 10 µl 100 bp ssODN 5 Comp 5 bp 1 1/13 7.7%
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Figure 4. Generation of human neuronal cell lines containing missense mutations that cause neurological disorders. (A) Schematic 
representation of the MECP2 locus with the sgRNA 2 target sequence labelled. Site of double-strand break is indicated with arrowheads. 
ssODN molecule is shown with point mutation changes highlighted in upper case and the DSB to point mutation distance labelled. 
(B) Genomic DNA sequencing of two R306C positive clones. Both clones have the correctly inserted R306C point mutation as well as 
downstream deletions induced by sgRNA 2. The site of DSB is indicated by an arrowhead. (C) Schematic representation of a plasmid 
containing Cas9, sgRNA and EGFP expression constructs. (D) Genomic DNA sequencing of two R111G positive cell lines. (E) Genomic DNA 
sequencing of two R133C positive cell lines. (F) Genomic DNA sequencing of two T158M positive cell lines. (G) Schematic representation of 
part of the EEF1A2 locus, with sgRNA target sequences labelled and the ssODN donor molecule with point mutation alterations indicated in 
upper case. Sites of single-strand nicks are indicated with an arrowhead. Distances between each nick and the point mutation of interest are 
labelled. (H) Genomic DNA sequencing of the EEF1A2-D252H positive cell line.
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Again the MECP2 locus was targeted and a sgRNA that spans the 
stop codon was used, resulting in its targeting sequence being abol-
ished once a successful KI has occurred (Figure 5A). We chose to 
KI mCherry and use FACS analysis to provide an accurate estimate 
of KI efficiency, i.e. the percentage of mCherry positive cells in 
the whole population. Due to the large size of mCherry (711bp), a 
plasmid donor was used for targeting with 2.3kb and 1.2kb homology 
arms (Figure 5A). FACS analysis determined the percentage of 
mCherry positive cells in the entire population to be 0.015% 
(Figure 5B). Out of 29 single-cell clones assessed, 25 were MECP2-
mCherry positive as judged by a PCR assay that used a forward 
primer in mCherry itself and a reverse primer in the MECP2 gene 
locus, outwith the targeting vector (Figure 5C). Positive cell lines 
were confirmed by immunofluorescence and Western blot analysis 
Figure 5. Endogenous knock-in of an mCherry tag into the MECP2 locus in LUHMES cells. (A) Schematic representation of the MECP2 
locus with the sgRNA C target region labelled, the targeting vector, and the recombined genomic DNA allele. Positions of primers used 
for screening purposes in (C) are indicated. (B) Flow cytometry analysis of WT cells and cells that were transfected with Cas9, sgRNA 
and targeting plasmid. (C) PCR screening of genomic DNA from single-cell clones that were identified as being mCherry positive by flow 
cytometry. (D) Immunofluorescence imaging of WT cells and two single-cell clones using DAPI and antibodies probing for MeCP2 and MAP2. 
Images are slices through a z-stack. Scale bar represents 50 µm. (E) Immunoblot analysis of WT cells and four MECP2-mCherry positive 
clones. (F) Immunoblot analysis of WT cells, two MECP2-mCherry positive clones and two MECP2-mCherry negative clones. (E+F) Top panel 
probe: MeCP2. Middle panel probe: mCherry. Bottom panel probe: Histone H3 as a loading control.
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(Figure 5D+E; Supplementary Figure 4), and two negative cell lines 
(as determined by PCR analysis) were confirmed by Western blot 
(Figure 5F, clones 22 + 27). These experiments demonstrate suc-
cessful CRISPR-mediated KI of a large tag into LUHMES cells, 
thus highlighting the variety of genetic alterations that are feasible 
in this cell line.
Discussion
The LUHMES cell line is an immortalised neuronal cell line 
derived from an 8-week old female foetus that is highly prolif-
erative in a stem-cell like, yet neuronal-committed state, and can 
differentiate into mature dopaminergic neurons via addition of 
tetracycline to the cell culture medium (Scholz et al., 2011). A 
key advantage of LUHMES cells compared to other neuronal 
differentiation systems is the near 100% homogeneity of differen-
tiation into a population of mature, post-mitotic neurons, without 
the presence of astrocytes or other non-neuronal cell types. This 
homogeneity is extremely beneficial for “bulk population” experi-
ments such as RNA-sequencing, Western blot analysis and Hi-C 
studies where mixed cell populations could result in skewed data 
and difficult-to-interpret results. Here we describe methods for 
the successful genetic manipulation of LUHMES cells in order to 
create targeted protein knock-out, disease-causing point mutation 
knock-in, and large tag knock-in cell lines.
The combination of targeted mutagenesis with rapid generation 
of mutant neuronal cells provides a potentially valuable tool for 
neuroscience. These manipulated cell lines may complement 
in vivo datasets as disease phenotypes obtained using mouse mod-
els can be coupled with electrophysiological and biochemical 
data from human neurons in order to bridge the gaps between 
disease causing mutations, neuronal malfunction and whole organ-
ism pathophysiology. The ease of high-throughput differentiation 
of this cell line in 96-well plates opens the door towards drug 
screening programs like those already being pursued using hiP-
SCs (Cao et al., 2016; Lee et al., 2012). As a potential alterna-
tive, LUHMES cells simplify the differentiation procedure, speed 
up the differentiation time course, and ensure that a homogeneous 
population of mature neurons will be screened. Furthermore, 
although downstream applications of genetically modified LUHMES 
cells might be limited by their dopaminergic lineage, removal 
of supplements from the differentiation medium results in the 
production of tyrosine hydroxylase-negative cells, that differenti-
ate into morphologically and immunocytologically mature neurons 
for study (Scholz et al., 2011).
Bi-allelic X chromosome targeting
We observed that both alleles undergo HDR at a rather high fre-
quency, regardless of whether the 2nd allele is on an autosome or the 
inactive X chromosome. For the MECP2-R111G targeting experi-
ment, out of the seven cell lines that contained a KI of R111G on 
the active X allele, six also contained a KI on the inactive X allele. 
Likewise for the MECP2-R133C targeting experiment, the two 
R133C positive cell lines had undergone HDR repair on both alle-
les. It is however important to note that not all HDR events result in 
a clean integration. Partial recombination within the short distance 
of a 100bp ssODN (Figure 6A+B) and multiple integrations of the 
ssODN in tandem at a locus have been observed (Figure 6E), as 
well as recombined alleles containing INDELs at the site of sgRNA 
DSB (Figure 4B).
Surprisingly we found in more than one case that the MEPC2 allele 
on the inactive X chromosome underwent HDR, while the allele on 
the active X chromosome acquired an INDEL. It is expected that 
the active allele would be more open and accessible to recombina-
tion compared to the inactive X chromosome, however at least two 
cell lines were observed that have an active allele INDEL and an 
inactive allele KI (Figure 6C+D). These data reflect the large vari-
ety of genomic alterations that can be induced by CRISPR/Cas9 
and demonstrate the somewhat unpredictable nature of HDR- 
mediated gene targeting. Our experiments stress the need for a 
sgRNA-induced DSB as close as possible to the desired genetic 
alteration and highlight the importance of donor molecule 
design; in particular use of a sgRNA-complementary ssODN that 
has minimal mismatches upstream of the PAM seems to be most 
efficient.
Further optimisation of KI of large tags
In the mCherry KI experiment the plentiCRISPR plasmid 
(Sanjana et al., 2014) was used to deliver Cas9 and sgRNA, and 
positively transfected cells were selected using the co-encoded 
puromycin resistance gene (Figure 2B), while the mCherry 
targeting vector was delivered as a separate plasmid. It is possible 
that a proportion of transfected cells did not take up both plasmids 
(Assur et al., 2012) and this could explain the low targeting effi-
ciency of 0.015% observed in this experiment. As such, a double 
antibiotic selection method could increase HDR efficiencies 
when plasmid donors are necessary, for example by including an 
expression cassette for the bacterial blasticidin resistance gene 
(bsr) in the targeting plasmid and selecting with both puromycin 
and blasticidin.
Design of targeting vectors with alternative homology arm 
lengths could also improve the efficiency of KI. Indeed, others 
have reported comparable efficiencies with homology arms of 175 
bp compared to 700–900 bp in human cell lines (Natsume et al., 
2016). Alternatively, the use of drugs to inhibit the NHEJ pathway 
could also boost HDR in LUHMES cells (Maruyama et al., 2015; 
van Overbeek et al., 2016). Even without these enhancements, 
the power of FACS sorting allows efficient selection for the small 
number of positive cells within a large population and, as demon-
strated here, this results in a stream-lined and efficient protocol for 
CRISPR-mediated tag KI in LUHMES cells.
Concluding remarks
In conclusion, we have demonstrated efficient genetic manipulation 
of the LUHMES female human neuronal cell line to create a number 
of lines harbouring neurological disease-causing point mutations 
(Figure 7). The future phenotypic assessment of these cell lines will 
provide significant insight into the molecular mechanisms of these 
diseases. Using the methods described here LUHMES cells have 
the potential to be a valuable tool for exploration of the underlying 
biology of neurogenetic disorders and may pave the way for drug 
development and therapeutic strategies in the future.
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Experimental procedures
Plasmids and cloning
All CRISPR plasmids were purchased from Addgene and origi-
nated from the Zhang lab; pX458 (48138), pX461 (48140) and 
plentiCRISPRv2 (52961). The crispr.mit.edu online webtool was 
used for sgRNA design (Table 2). Cloning of sgRNAs into CRISPR 
plasmids was performed following the protocol from the Zhang lab, 
available online at genome-engineering.org and described in Ref 
(Cong et al., 2013). All ssODNs were ordered as 100bp or 110bp 
(Sigma, desalted) or 200bp (IDT, PAGE-purified) oligonucleotides 
(Table 3). Gateway cloning (Invitrogen) was used to create the 
mCherry targeting plasmid. The pmaxGFP plasmid for optimisa-
tion of Nucleofection techniques came in the Nucleofection kit 
provided by Lonza.
The R306C targeting plasmid was created by firstly performing 
a PCR reaction using Phusion polymerase in GC buffer (NEB) 
with approximately 100–250 ng LUHMES genomic DNA in a 
25 µl reaction volume (Table 4). Subcloning was performed using 
2 µl of this PCR mix with the Zero Blunt TOPO PCR cloning kit 
Figure 6. Analysis of range of mutations induced by CRISPR/Cas9 in LUHMES cells. (A+B) Partial recombination can occur with the 
ssODN molecule. (A) Three single cell clones from the R111G targeting experiment, two of which contain a partially recombined allele. 
(B) Two single cell clones from the R133C targeting experiment; clone 1 has an allele with 2/3 of the KI residues, clone 2 has an allele with only 
1/3 of the KI residues. (C) Genomic DNA sequencing of a single clone reveals one allele to contain two point mutations and the other allele 
to contain a 6bp deletion, yet cDNA sequencing identifies the HDR to have occurred with the allele on the inactive X chromosome. (D) cDNA 
sequencing identifies the allele on the active X chromosome having undergone recombination, with all three point mutations integrated plus 
a single base pair insertion. (E) Sequencing of single-cell clones reveals duplication events occurring as a result of multiple recombination 
events with the ssODN. (A,B,C,D,E) mPAM - silent point mutation that abolishes the PAM site for each sgRNA. Rett-syndrome causing point 
mutations of interest and silent restriction enzyme target sequence point mutations are highlighted with arrows.
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 (Invitrogen) and 2 µl of the subcloning reaction was transformed 
into DH5α cells. The following day two colonies were picked into 
3 ml cultures of LB/kanamycin and grown overnight by shaking 
at 37°C. The next day plasmids were extracted from 1.5 ml of cul-
ture using the Plasmid Miniprep kit (Qiagen) and sequenced using 
primers spanning the MECP2 locus. After sequencing confirmed 
error-free incorporation of the MECP2 fragment into the pTOPO 
vector, 50 ml cultures of LB/kanamycin were set up using the 
remaining 1.5 ml of bacterial culture and grown overnight by 
shaking at 37°C. The next day plasmids were extracted using the 
Plasmid Maxiprep kit (Qiagen). This plasmid was subjected to 
site-directed mutagenesis using the QuickChange II XL kit 
(Agilent) following the manufacturer’s instructions. Two rounds 
of mutagenesis PCRs were used to incorporate first the R306C 
point mutation, and then two PAM-abolishing point mutations for 
two separate sgRNAs to create the final targeting vector.
Tissue culture
LUHMES cell (ATCC cat# CRL-2927, RRID CVCL_B057, 
kind gift from Dr Tanja Waldmann) tissue culture medium and 
methods were as described in Reference (Scholz et al., 2011) with 
some minor alterations. All vessels were coated in poly-L-ornithine 
(PLO) and fibronectin overnight at 37°C. Proliferating LUHMES 
cells were seeded at 2x106 cells/T75 every 2 days. For differen-
tiation, 2.5x106 cells were seeded in a T75 for the first 2 days 
of the protocol and on day 2 cells were seeded as follows: 
8x106 cells/T75 and 0.15x106 cells/coverslip. During differentiation 
a half-media change was performed on day 6 and neurons were 
harvested for protein or fixed for immunostaining on day 9.
Transfection methods
LUHMES cells were transfected by Nucleofection (Lonza) using 
a Basic Nucleofector kit for primary neurons (VAPI-1003) and 
a Nucleofector II device. LUHMES cells were dissociated with 
4ml of trypsin (Gibco), centrifuged at 13000 rpm for 5 minutes 
and resuspended in PBS for cell counting using a Scepter device 
(Millipore). Aliquots of 2x106 cells were pipetted into 15 ml falcons 
and these were centrifuged for 5 minutes at 13000 rpm. PBS was 
removed from all 15 ml falcons and the appropriate volume of each 
plasmid/ssODN was added to each tube (see Table 1). One by one 
cells and plasmids were then resuspended in 90 µl of the Nucleo-
fection solution and immediately transferred into a cuvette (pro-
vided in the kit) for electroporation in the Nucleofector II device. 
After electroporation, RPMI medium (Sigma) was added using the 
pipette provided in the kit and cells were moved into 15 ml fal-
cons and incubated at 37°C for 5 minutes before plating out into 
6-well plates containing pre-warmed LUHMES proliferation media. 
Media was changed after a minimum of 4 hours.
FACS sorting
For flow cytometry sorting of single LUHMES cells into each well 
of a 96-well plate, Greiner plates were pre-coated overnight in 
PLO/fibronectin as described in Reference (Scholz et al., 2011). 
Proliferation medium was supplemented with 1X B27 (Sigma), 100 
U/ml penicillin (Gibco) and 100 µg/ml streptomycin (Gibco) and 
100 µl was added to each well of the 96-well plates. LUHMES cells 
were trypsinised and centrifuged in a 15 ml falcon tube at 13000 
Figure 7. Simple targeting pipeline for generation of genetically 
modified LUHMES cell lines using CRISPR technology. Cells 
are Nucleofected with the plasmids and ssODNs necessary for 
the specific targeting experiment and taken for FACS sorting two 
days later. After approximately 10 days single cell colonies will have 
expanded enough to require dissociation and transfer to 24-well 
plates. From 24-well plates cells can be frozen down for storage in 
liquid nitrogen and some cells harvested for genomic DNA. The first 
step of the screening strategy is to perform an RFLP assay to identify 
a subset of clones that will be taken for genomic DNA sequencing 
which will identify cell lines that are positive for a clean KI. For more 
detailed information see methods and materials.
Nucleofection:
+ pX458 - Cas9 + sgRNA + GFP
± ssODN
± Targeting vector
FACS
Move to 24-well plates
~1.5 weeks
Liquid nitrogen Genomic DNA
RFLP Assay
Sequencing
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Table 2. Sequences of sgRNAs used in this study. All sgRNAs are 20 nucleotides long. 
Those without a 5’ G nucleotide had one added for efficient U6 promoter transcription to 
make a 21 nucleotide sequence.
sgRNA name Experiment Sequence (5’ ➔ 3’)
sgRNA A Knock-out of MeCP2 AGAAGCTTCCGGCACAGCCG
sgRNA B Knock-out of MeCP2 CGCTCCATCATCCGTGACCG
sgRNA 1 Knock-in of R306C-MECP2 CCATCAAGAAGCGCAAGACC
sgRNA 2 Knock-in of R306C-MECP2 GACGGTCAGCATCGAGGTCA
sgRNA 3 Knock-in of R111G-MECP2 GGACACGGAAGCTTAAGCAA
sgRNA 4 Knock-in of R133C-MECP2 AAAAGCCTTTCGCTCTAAAG
sgRNA 5 Knock-in of T158M-MECP2 GATTTTGACTTCACGGTAAC
sgRNA 6 Knock-in of T158M-MECP2 ATTTTGACTTCACGGTAACT
sgRNA 1 Knock-in of D252H-EEF1A2 GCTTGTCCGTGGGGCGCGTG
sgRNA 2 Knock-in of D252H-EEF1A2 CAGGACGTGTACAAGATTGG
sgRNA C Knock in of mCherry tag into MECP2 TTAGCTGACTTTACACGGAG
Table 3. Sequences of ssODNs used in this study. Point mutation changes from the wild-type, endogenous sequence are highlighted in 
bold, with the point mutation of interest in bold red.
ssODN Experiment Sequence (5’ ➔ 3’)
1 Knock-in of R306C-MECP2
GAGTCTTCTATTCGATCTGTGCAAGAGACCGTACTCCCCATCAAGAAGTGCAAGACCCGGGAGACGGT 
CAGCATCGAAGTCAAAGAAGTGGTGAAGCCCCTGCTAGTGTC
2 Knock-in of R306C-MECP2
GACACCAGCAGGGGCTTCACCACTTCCTTGACCTCGATGCTGACCGTCTCGCGGGTCTTGCACTTCT 
TGATGGGGAGTACGGTCTCCTGCACAGATCGAATAGAAGACTC
3 Knock-in of R111G-MECP2
CTTACTTACTTGATCAAATACACATCATACTTCCCAGCAGAGCGTCCAGATTTGCCTTGCTTAAGCTTCCGT 
GTCCAGCCTTCAGGCAGGGTGGGGTCAT
4 Knock-in of R133C-MECP2
CAGGGATGTGTCGCCTACCTTTTCGAAGTACGCAATCAATTCGACTTTAGAGCAAAATGCTTTTCCCTGGG 
GACTGTGGGGACAAACAGAAAGACACAAG
5 Knock-in of T158M-MECP2
GGCTTCTTAGGTGGTTTCTGCTCTCGCCGGGAGGGGCTCCCTCTGCCAGTTACCATGAAGTCAAAAT 
CATTAGGGTCCAGGGATGTGTCGCCTACCTTTT
6 Knock-in of D252H-EEF1A2
TAAGGAGGGCAACGCAAGCGGCGTGTCCCTGCTGGAGGCCCTGGACACCATCCTGCCTCCCACG 
CGCCCCACGGACAAGCCCCTGCGCCTGCCGCTGCAGCACGTTTATAAGATCGGCGGTGAGCAAGGGC 
GCTGTGCTGGAGCTCCTGCCTGGCCAGCTCTGCCTGCCCTAGACCAGGGGCCCCTACAAGGCATCTCAA
rpm for 5 minutes and resuspended in 1 ml of Advanced DMEM/
F12 supplemented with 10 µM HEPES. Cells were sorted using a 
100 µm nozzle with a FACSaria machine at room temperature. Six 
days later 100 µl of proliferation medium was added to the 96-well 
plates.
Targeting pipeline in LUHMES cells
Day 1 – Thaw low passage number LUHMES
Day 3 – Passage once
Day 5 – Nucleofect and change media after 4 hours
Day 7 – Take for FACS sorting of single GFP-positive cells into a 
96-well plate
Day 13 – Top up 96-well plate with 100 µl of media
Day 16 – Start moving clones from 96-well plates to 24-well 
plates
Day 17 onwards – Split individual clones in 24-well plates as they 
are confluent, freeze down half the well for liquid nitrogen, move 
the other half to a new well in a 24-well plate for genomic DNA.
Genomic DNA isolation
For extracting genomic DNA from tissue culture samples, Puregene 
Core Kit A (Qiagen) was used following the manufacturer’s instruc-
tions. Occasionally, when RNA and DNA were required from a 
single sample, the Allprep DNA/RNA Mini kit (Qiagen) was used.
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For large scale genomic DNA extraction from LUHMES single cell 
clones in a 24-well plate an alternative approach was used. Indi-
vidual clones were trypsinised and harvested when confluent and 
incubated in 400 µl lysis buffer (50 mM Tris pH 9.0, 20 mM EDTA 
pH 8.0, 40 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K) overnight 
at 55°C. The next day 300 µl saturated NaCl was added to each 
sample, mixed by vigorous shaking for 1 minute, and centrifuged 
at 14000 rpm for 10 minutes at room temperature. The superna-
tant was transferred to an Eppendorf containing 500 µl isopropanol, 
mixed by inversion and centrifuged at 14000 rpm for 10 minutes at 
4°C. The DNA pellet was washed with 750 µl 70% ethanol, mixed 
by inversion, and centrifuged at 14000 rpm for 10 minutes at 4°C. 
The DNA pellet was air dried, resuspended in 50 µl TE and allowed 
to dissolve at 55°C overnight.
RNA isolation and preparation of cDNA
RNA was extracted using an RNeasy Mini Kit (Qiagen) follow-
ing manufacturer’s instructions. RNA concentration was meas-
ured using a Nanodrop 1000 (Thermo Scientific) and 10 µg RNA 
was taken for DNase1 treatment (Ambion) for 1 hour at 37°C. 
Table 4. Sequences of primers used in this study. For Gateway cloning primers, sequence in red is the att tag, sequence in black is 
homologous to MECP2 or mCherry.
Experiment Primer name Sequence (5’ ➔ 3’)
Sequence CRISPR 
plasmids pLKO1_5 GACTATCATATGCTTACCGT
Cloning of pR306C 
targeting vector
hMeCP2_6F CGCTCTGCTGGGAAGTATGA
hMeCP2_5R CCAACTACTCCCACCCTGAA
Site-directed mutagenesis 
of pR306C targeting 
vector
R306C_F TCCCCATCAAGAAGTGCAAGACCCGGGAG
R306C_R CTCCCGGGTCTTGCACTTCTTGATGGGGA
PAMs_F ATCGAGGTCAAAGAAGTGGTGAAGCCCCTGCTAGTGTCCACCCTCG
PAMs_R CGAGGGTGGACACTAGCAGGGGCTTCACCACTTCTTTGACCTCGAT
Gateway cloning of 
mCherry targeting vector
attB1_MeCP2_intron2F GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACAGCCCAAATTCCTAAA
attB4_MeCP2_stopR GGGGACAACTTTGTATAGAAAAGTTGGGTG GCTAACTCTCTCGGTCACGG
attB4r_mCherry_IF_Tm GGGGACAACTTTTCTATACAAAGTTGTTATGGTGAGCAAGGGCGA
attB3r_mCherry_IF_Tm GGGGACAACTTTATTATACAAAGTTGTCTACTTGTACAGCTCGTCCATGC
attB3_MeCP2_stopF GGGGACAACTTTGTATAATAAAGTTGTGACTTTACACGGAGCGGAT
attB2_MeCP2_8R GGGGACCACTTTGTACAAGAAAGCTGGGTAGCAGAAATGGAAGGGGAGAA
Phusion PCR for R306C 
clones
hMeCP2_F AGCTCCTTGTCAAGATGCCT
hMeCP2_R AGTCCTTTCCCGCTCTTCTC
Phusion PCR for R111G 
clones
Intron2_2F TCCCTTGAAGTGCGACTCAT
1_R CCTCTCCCAGTTACCGTGAA
Phusion PCR for R133C 
clones
Intron3_2F CAGACGAGTGAGTGGCTTTG
2_R AGTCCTTTCCCGCTCTTCTC
Phusion PCR for T158M 
clones
Intron3_2F CAGACGAGTGAGTGGCTTTG
3_R CAATCCGCTCCGTGTAAAGT
Phusion PCR for MECP2-
mCherry clones
1 TCCCTTGAAGTGCGACTCAT
2 GGACGGAGGAAGGGAAAGAA
3 GGGGACAACTTTTCTATACAAAGTTGTTATGGTGAGCAAGGGCGA
Phusion PCR for EEF1A2-
D252H clones
hD252H_1F TTCCTCATCTCAAAGGGCACG
hD252H_2R CAAGTTTAGCCTGAACAGCAGTA
Sequencing of EEF1A2-
D252H clones
hD252H_2F CCCACAGAAGTGTGTGGTAAG
hD252H_2R TTGGAGACAGCCAGTCTTG
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DNA-free RNA concentration was measured using a Nanodrop 
and 1 µg used for cDNA synthesis using qScript cDNA Supermix 
(Quanta).
T7 Endonuclease I assay
Phusion polymerase in GC buffer (NEB) was used to PCR amplify 
100–250 ng genomic DNA in a 50 µl reaction volume (Table 4) 
and 5 µl of the reaction was ran out on an agarose/TAE gel. To the 
remaining 45 µl PCR mix, 5 µl of Buffer 2 (NEB) was added and 
the reactions were heated at 95°C for 10 minutes in a PCR machine 
and cooled slowly to 25°C to produce heteroduplexes. Each 
reaction was split in half and to one half 1 µl of T7E1 (NEB) 
was added. All reactions were incubated at 37°C for 30 minutes, 
followed by addition of 10 µl of 6X loading dye and analysis on 
an agarose/TAE gel.
Restriction fragment length polymorphism assay
Phusion polymerase in GC buffer (NEB) was used to PCR 
amplify 100–250 ng genomic DNA in a 25 µl reaction volume 
(Table 4) and 10 µl of each PCR was run out on an agarose/TAE 
gel. To the remaining PCR mix 29 µl of H2O, 5 µl of CutSmart 
buffer (NEB) and 0.5 µl of the appropriate enzyme was added. 
Reactions were incubated at the necessary temperature and length 
of time for each enzyme and were analysed by electrophoresis in an 
agarose/TAE gel.
PCR and sequencing analysis
Phusion polymerase in GC buffer (NEB) was used to PCR 
amplify 100–250 ng genomic DNA in a 25 µl reaction volume 
(Table 4) and 10 µl of the reaction was ran out on an agarose/TAE 
gel for confirmation of efficient PCR amplification. Each ampli-
con was subcloned using the Strataclone blunt PCR cloning kit 
(Agilent Technologies) following the manufacturer’s instructions 
and transformed into Strataclone Solopack competent bacteria 
(Agilent Technologies). The next day single colonies were picked 
and colony PCR was performed using either Phusion polymerase 
or DreamTaq polymerase (Thermo Fisher) in a 25 µl volume 
(Table 4). For confirmation of PCR, 10 µl of each colony PCR 
reaction was analysed by agarose/TAE gel electrophoresis. 
Positive colony PCRs were treated with 0.25 µl Exonuclease I 
(NEB) and 0.25 µl FastAP alkaline phosphatase (Thermo) at 37°C 
for 15 minutes followed by inactivation at 85°C for 15 minutes. 
Sequencing was performed using BigDye Terminator v2.1 reaction 
mix with 3.5 µl of each sample and 3.2 pmol of primer.
Western blot analysis
Whole cell protein extracts were prepared by homogenising cell 
pellets in NE1 buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1 mM 
MgCl2, 0.5 mM DTT, 0.1% Triton-X 100, 20% glycerol and 1X 
protease inhibitor cocktail (Roche)). Homogenates were treated 
with benzonase for 15 minutes at room temperature and then meas-
ured for protein concentration using a Bradford assay (Protein Assay 
Dye Reagent concentrate, BioRad). Extracts were loaded onto pre-cast 
4–20% Mini-PROTEAN TGX gels (BioRad) and ran at 200V for 
approximately 30–40 minutes. Gels were transferred onto nitrocel-
loluse membrane by transfer at 30V overnight at 4°C. Membranes 
were blocked in 5% milk, 0.1% Tween-20 in TBS for 30 minutes 
and probed with primary antibodies (Table 5) in blocking solu-
tion for 1 hour at room temperature. IRDye 800CW α-mouse and 
IRDye 680LT α-rabbit secondary antibodies (Licor) were probed 
for 1 hour at room temperature in blocking buffer at a concentration 
of 1:10000 and scans were taken using a Licor Odyssey machine.
Immunofluorescence imaging
Cells grown on coverslips were fixed in 4% formaldehyde for 10 
minutes, permeabilised with 0.2% Triton-X/PBS for 10 minutes 
and blocked for 30 minutes in 10% fetal bovine serum in PBS 
(FBS/PBS). Coverslips were incubated in the presence of primary 
antibodies (Table 5) in 1% FBS/0.1% Tween-20/PBS for one hour 
room temperature. Coverslips were washed with 0.1% Tween-20/
PBS, and incubated for one hour at room temperature with Alexa 
Fluor secondary antibodies (1000X dilution, Invitrogen) in 1% 
FBS/0.1% Tween-20/PBS. Secondary antibodies: α-mouse 488, 
α-rabbit 555 and α-chicken 633. Coverslips were finally stained 
with DAPI (5000X dilution in PBS) for 10 minutes at RT and 
mounted onto microscope slides using Prolong Diamond solution 
(Thermo Fisher). Z-stack images were taken using a Leica SP5 con-
focal microscope and z-stacks were flattened and processed using 
ImageJ 1.47v software.
Other microscopy
Phase contrast images were taken on an Eclipse TS100 inverted 
microscope (Nikon) using QCapture Pro software version 5.1.1.14 
(QImaging). UV fluorescence was used to take GFP pictures of 
Table 5. Details of antibodies used in this study. Antibodies used for Western blot analysis (WB) or 
immunofluorescence (IF). Cat number – catalogue number.
Antibody Company + Cat Number Experiment Dilution Species RRID
MeCP2 Sigma 7443 WB; IF 1000X Mouse monoclonal AB_477235
MeCP2 Sigma 6818 WB 1000X Mouse monoclonal AB_262075
GAPDH Cell Signalling 5174 WB 5000X Rabbit monoclonal AB_10622025
H3 Abcam 1791 WB 5000X Rabbit polyclonal AB_302613
mCherry Abcam 167453 WB, IF 1000X Rabbit polyclonal AB_2571870
Neurofilament Covance SMI-311R-100 IF 500X Mouse monoclonal AB_509991
MAP2 Abcam 5392 IF 5000X Chicken polyclonal AB_2138153
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cells. The IncuCyte microscope (Essen Biosciences) was used 
to take phase contrast and GFP fluorescent images and ZOOM 
software (Essen Biosciences) was used to extract and export the 
images.
RNA FISH
RNA FISH was performed as described in (Chaumeil et al., 
2008). BAC-based probes were used for detection of MECP2 and 
ATRX (RP11-119A22 and RP11-42M11 respectively). Probes for 
XIST RNA detection have been used previously, as described in 
(Chaligne et al., 2015).
Data availability
Zenodo: Efficient and versatile CRISPR engineering of human 
neurons in culture to model neurological disorders, DOI 10.5281/
zenodo.163342 (Shah et al., 2016)
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Supplementary Material
Supplementary Figure 1. Optimisation of Nucleofection in LUHMES cells. (A) Karyotyping of LUHMES pre-neuronal cells confirms 
a normal ploidy. (B) RNA FISH of these female cells demonstrates that X inactivation is already established in the pre-neuronal cells. 
Scale bar is 5 µm. (C) Trials of various electroporation programs using the Basic Nucleofector kit for primary neurons. (D) Comparison of 
different plasmid amounts on cell viability. (E) Comparison of phenol:chloroform:isoamylalcohol plasmid purification on cell viability. 
(F) Comparison of cell viability when endotoxin-free plasmids are used, when the cells are incubated at 37˚C in RPMI for 5 minutes 
(RPMI) and when they are centrifuged before plating (spin). All scale bars are 200 µm.
Supplementary Figure 2. Analysis of MeCP2 KO cell lines. (A) Representative phase contrast and GFP fluorescence images of LUHMES 
cells 25 hours after Nucleofection. Scale bar is 200 µm. (B) Immunoblot detection of MeCP2 protein in single cell clones derived from the 
plentiCRISPR targeting experiment using an N-terminal and a C-terminal antibody. GAPDH is probed for a loading control. Note: E10 = 
WTC, D10 = KO1 and H4 = KO2 in Figure 2. (C) Sequencing of cDNA from single LUHMES clones identifies mixed cell populations by 
the presence of multiple cDNA alleles per clone. Each colour block denotes an individual clone.
Supplementary Figure 3. Optimisation of CRISPR-mediated point mutation knock-in of Rett syndrome causing missense mutations. 
(A) hMeCP2_F and hMeCP2_R PCR of WT cells and clones that have been targeted with components shown in Figure 3A, in preparation 
for RFLP analysis. (B, C, D) Schematic representation of R111G (B), R133C (C) and T158M (D) targeting experiments. Two sgRNAs are 
labelled in (D), each sgRNA was used in a separate targeting experiment. Sites of DSB and PAM sites are indicated for each sgRNA, with 
DSB to point mutation distances highlighted. Mutations that introduce a novel restriction enzyme target sequence are also labelled.
Supplementary Figure 4. MeCP2-mCherry positive cells lines as determined by immunofluorescence imaging. Neurons were 
differentiated until day 9 and then fixed and stained for neurofilament (NF), MAP2, mCherry and DAPI. Images are flattened z-stacks. Scale 
bar is 50 µm.
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This is a very clear and useful article describing protocols for the genetic modification of LUHMES cells.
The paper is well written. The results are going to be helpful to the research community, not least because
the authors also mention approaches that did not work. In view of the increased interest in using CRISPR
engineering to modify human neurons and mimic disease in cell cultures, this paper will likely increase the
number of laboratories that are interested in utilising LUHMES cells.
 
There are only four minor concerns with the current edition of the manuscript:
Somewhere in the paper the authors should describe the approximate proportion of differentiated
LUHMES neurons that express tyrosine hydroxylase (TH). This proportion has been reported to
vary greatly between laboratories, and it would be helpful if this outcome is described briefly in the
text (and possibly with a photo).
 
There is no description of what the different changes in phenotype the different genetic
manipulations cause. Obviously, a detailed account is beyond the scope of the present
manuscript, but a hint of the outcomes would be helpful. Alternatively, it should be clearly stated
that this is the focus of another later paper.
 
The cells used in this paper (ATCC cat# CRL-2927, RRID CVCL_B057) are cited as a “kind gift
from Dr Tanja Waldman”. ATCC stipulates “Please note that ATCC generally does not allow
transfers of ATCC Materials or Progeny (“Unmodified Materials”). This is because ATCC Materials
may be purchased directly from ATCC with limited disruption to research. […] Please note that
there may be a fee for transferring Unmodified Materials to a third party as this falls outside of our
general distribution practices.”
(source: .https://www.atcc.org/~/media/PDFs/ATCC%20MTA%20FAQs_2013.ashx)
The authors should clarify briefly in the manuscript that they and Dr Waldman have obtained the
appropriate permits that would make this gift comply with ATCC rules.
 
Since Wellcome Open Research is currently only indexed in PubMed Central, and not yet indexed
in PubMed, the authors should promote the dissemination of this helpful manuscript via other
channels (e.g. citing it in social media, indexed reviews and future papers).
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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The authors present interesting data about the generation of new genetically engineered models for
studying neurological disorders. In particular, the authors present optimized methods to generate KOs,
KIs and reporter alleles in LUHMES cells. Such systems are of great relevance to establish direct links
between disease-causing mutations and phenotypes.
The manuscript is well written, has an important technical message, and is of acceptable scientific
standard. I recommend its publication.
 
However, there are some points that could be enhanced if some changes are made, or further clarification
is provided. Mainly:
The title should be changed to better describe the conclusions and cell type used in the study.
“Efficient and veritable” could be changed to “optimized”, and “human neurons in culture” could be
changed to “Immortalized Human Dopaminergic Neuronal Precursor Cells, LUHMES cells”
 
The following sentence does not reflect recent findings - “Furthermore, there is still debate as to the
robustness of the epigenome in iPSCs after reprogramming”. (
). Please update accordingly.http://www.nature.com/nbt/journal/v33/n11/full/nbt.3388.html
 
Fig. 2D. The authors claim that KO1 clone is a homozygous KO clone, with both alleles harbouring
a 9bp deletion. Although this is a fair assumption based on the data presented, this result could be
based on technical artefact, such as PCR bias (only one the X chromosomes being amplified), or
deletion of the primer binding sites due to big deletion generated after CRISPR cutting, or
screening of insufficient bacterial clones to provide enough resolution. It would be clarifying if
authors could provide further data to prove this point, like PCR using different primers pairs, further
away from the cut site.
 
Table 1. Taking into account that all positive clones in the “Number of KI clones” have been Sanger
sequenced, it would be of relevance if the authors could discriminate how many of those are
homozygous KI/KI, or heterozygous KI/WT or KI/indel. This information should also be added to
the main text.
 
In line with the comment above, similar information should be provided in the “Knock-in of a large
tag into the endogenous MECP2 locus” section, mainly the discrimination of many clones were
homozygous tag/tag, or heterozygous Tag/WT or Tag/indel.
 
Overall, it is an important study by providing standardized methods for gene editing in LUHMES cells,
which I believe is of important value for the scientific community.
We have read this submission. We believe that we have an appropriate level of expertise to
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